pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›BEYFORTUS
drug · antibody
save

BEYFORTUS

updated 3mo ago
by $AZN ASTRAZENECA PLC🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval20 co-mentions · 5 sources
  • drugnirsevimab20 co-mentions · 5 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

targets

Fusion glycoprotein F0

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand
BEYFORTUS
trade names
Beyfortus
generic
NIRSEVIMAB-ALIP
MOA
12.1 Mechanism of Action BEYFORTUS is a monoclonal antibody with anti-RSV activity [see Microbiology (12.4) ] .
indication
1 INDICATIONS AND USAGE BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. BEYFORTUS is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor indicated for the prevention of RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. ( 1 ) Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 28m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?